Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab vs tocilizumab in refractory or relapsing Takayasu arteritis
2018-003753-13Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in Takayasu arteritis (TAK) comparing Infliximab with Tocilizumab (2 arms). Started Dec 2018; status: active.
02
Drugs
infliximabtocilizumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on 2018-003753-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003753-13.